BRAF and neoplasm: The estimated RFS (HR 0.52, 95% CI 0.43-0.63) and DMFS (HR 0.56, 95% CI 0.44-0.71) both favoured the dabrafenib–trametinib arm.31 In a subgroup analysis, patients with a tumour BRAF V600E mutation (91%) in particular appeared to derive benefit in terms of OS (HR 0.75, 95% CI 0.58-0.96) and RFS (HR 0.52).